Subscribe

Huadong Medicine Co., Ltd (000963.SZ)

CNY31.43 +1.49 (+4.98%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address No. 866 Moganshan Road 310011
Hangzhou, CN
CEO Liang Lv
Website eastchinapharm.com
IPO 2000-01-27
ISIN CNE0000011S1

Explore sections of this company profile

Description

Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY31.43 +1.49 (+4.98%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
15M
Beta
0.12
Float Shares
733.82M
Free Float %
41.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.69% -2.12% -13.48% -19.25% -30.90% -26.44% -33.07% -30.84% -45.06% +63.59% +3,156.98%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
31.43
DCF (Unlevered) 102.99 +227.7%
DCF (Levered) 99.72 +217.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 85% Bullish
Rating 2026-05 Change
Strong Buy 1 -1
Buy 10 0
Hold 1 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
4.60
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +4.1% Q1'26: +4.2% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -3.0% Q1'26: +9.6% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +6.5% ★ Q1'26: -10.0% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +9.4% Q1'26: +10.6% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +13.8% ★ Q1'26: +14.5% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.1% Q1'26: -0.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.98× Q1'26: 1.09× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.20) × ERP
WACC = 91% × Ke + 9% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 104.05 Current price: 31.43
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
11 Rev. Ana.
1 EPS Ana. 		Dec 2027
12 Rev. Ana.
1 EPS Ana. 		Dec 2028
6 Rev. Ana.
1 EPS Ana.
Revenue
21.73B
est: 21.55B (+0.8%)
25.38B
est: 25.22B (+0.6%)
27.83B
est: 29.35B (-5.2%)
30.66B
est: 31.55B (-2.8%)
35.45B
est: 34.34B (+3.2%)
33.68B
est: 35.51B (-5.2%)
34.56B
est: 35.51B (-2.7%)
37.71B
est: 37.87B (-0.4%)
40.62B
est: 41.06B (-1.1%)
41.91B
est: 43.58B (-3.8%)
43.61B
est: 44.43B (-1.8%)
46.68B
45.27B – 49.37B
+5.1% YoY
49.35B
46.60B – 54.22B
+5.7% YoY
52.81B
50.52B – 56.96B
+7.0% YoY
EBITDA
1.74B
est: 2.27B (-23.4%)
2.13B
est: 2.66B (-19.6%)
2.56B
est: 3.09B (-17.2%)
3.20B
est: 3.32B (-3.7%)
3.59B
est: 3.62B (-0.6%)
3.46B
est: 3.74B (-7.6%)
3.32B
est: 3.74B (-11.3%)
3.78B
est: 3.99B (-5.3%)
4.32B
est: 4.32B (-0.1%)
5.09B
est: 6.50B (-21.7%)
5.13B
est: 6.63B (-22.6%)
6.96B
6.75B – 7.37B
+5.1% YoY
7.36B
6.95B – 8.09B
+5.7% YoY
7.88B
7.54B – 8.50B
+7.0% YoY
EBIT
1.58B
est: 1.92B (-17.9%)
1.92B
est: 2.25B (-14.6%)
2.29B
est: 2.62B (-12.7%)
2.88B
est: 2.82B (+2.1%)
3.19B
est: 3.07B (+3.9%)
3.02B
est: 3.17B (-4.6%)
2.81B
est: 3.17B (-11.5%)
3.15B
est: 3.38B (-6.7%)
3.59B
est: 3.67B (-2.1%)
4.34B
est: 5.08B (-14.5%)
4.10B
est: 5.18B (-20.8%)
5.44B
5.28B – 5.75B
+5.1% YoY
5.75B
5.43B – 6.32B
+5.7% YoY
6.15B
5.89B – 6.64B
+7.0% YoY
Net Income
1.10B
est: 1.21B (-9.0%)
1.45B
est: 1.40B (+3.6%)
1.78B
est: 1.82B (-2.0%)
2.27B
est: 2.22B (+2.2%)
2.81B
est: 2.97B (-5.2%)
2.82B
est: 2.96B (-4.7%)
2.30B
est: 2.75B (-16.3%)
2.50B
est: 2.65B (-5.6%)
2.84B
est: 2.88B (-1.4%)
3.51B
est: 3.35B (+4.9%)
3.41B
est: 3.81B (-10.3%)
3.91B
3.69B – 4.31B
+2.8% YoY
4.38B
4.14B – 4.83B
+12.0% YoY
5.06B
4.78B – 5.58B
+15.4% YoY
SGA
3.45B
est: 4.24B (-18.5%)
4.03B
est: 4.96B (-18.8%)
4.31B
est: 5.77B (-25.3%)
5.05B
est: 6.20B (-18.6%)
6.79B
est: 6.75B (+0.5%)
6.97B
est: 6.99B (-0.2%)
6.59B
est: 6.99B (-5.6%)
7.58B
est: 7.45B (+1.8%)
8.07B
est: 8.08B (-0.1%)
7.81B
est: 7.49B (+4.2%)
3.62B
est: 7.64B (-52.6%)
8.02B
7.78B – 8.49B
+5.1% YoY
8.48B
8.01B – 9.32B
+5.7% YoY
9.08B
8.68B – 9.79B
+7.0% YoY
EPS
0.70
est: 0.69 (+1.8%)
0.83
est: 0.80 (+4.2%)
1.02
est: 1.04 (-1.5%)
1.29
est: 1.27 (+1.9%)
1.61
est: 1.69 (-4.9%)
1.61
est: 1.69 (-4.6%)
1.32
est: 1.57 (-15.8%)
1.43
est: 1.51 (-5.3%)
1.62
est: 1.64 (-1.4%)
2.01
est: 1.91 (+5.3%)
1.95
est: 2.17 (-10.1%)
2.23
2.11 – 2.46
+2.8% YoY
2.50
2.36 – 2.75
+12.0% YoY
2.88
2.72 – 3.18
+15.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-28 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-27 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-26 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-25 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-22 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-21 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-20 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-19 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-18 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-15 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-14 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-13 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-05-12 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-05-11 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-05-08 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-05-07 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-05-06 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-30 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-29 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-28 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-27 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-24 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-04-23 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-22 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-21 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-20 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-17 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5
2026-04-16 B+ 3/5 4/5 4/5 5/5 1/5 3/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
3.27B
OE per share TTM
1.86
Owner's Yield
6.42%
Maintenance CapEx ratio
20.32%
Maint CapEx / Avg PPE
13.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 132 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 KraneShares MSCI All China Health Care Index ETF KURE 1.31% 1.05M 0.79%
2 HSBC MSCI China A UCITS ETF HMCT.L 0.20% 275.2K 0.30%
3 JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L 0.13% 30.7K 0.40%
4 Xtrackers Harvest CSI 300 China A-Shares ETF ASHR 0.11% 1.49M 0.65%
5 Amundi MSCI China A UCITS ETF Acc CNAA.L 0.10% 146.8K 0.35%
6 iShares MSCI China A UCITS ETF CNYA.L 0.10% 3.18M 0.40%
7 iShares MSCI China A UCITS ETF CNYE.MI 0.10% 104.8K 0.45%
8 Samsung KODEX China CSI300 ETF 283580.KS 0.10% 197.7K 0.12%
9 Xtrackers Harvest CSI300 UCITS ETF 1D ASHR.L 0.10% 309.0K 0.65%
10 Xtrackers MSCI China A UCITS ETF 1C XX2D.L 0.10% 133.2K 0.35%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
224.6K
Shares Outstanding
1.75B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Bo Chen Secretary of the Board — male
Liang Lv Chairman & GM — male
Renbo Qiu Chief Financial Officer & Head of Accounting Department — male
Zhongxing Zhang Deputy General Manager — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic